Study of Epigenetic Markers in Women With and Without Premenstrual Dysphoric Disorder PMDD Across the Menstrual Cycle

What this Trial Is About

Researchers are studying premenstrual dysphoric disorder PMDD, a mood disorder linked to hormone changes during the menstrual cycle. This research aims to identify epigenetic markers, which are biological signs in the DNA, that may help distinguish individuals with PMDD from those without symptoms. The study focuses on understanding how these markers vary between the follicular phase first half and luteal phase second half of the menstrual cycle, building on previous findings related to postpartum depression. The study involves two groups of female participants aged 18 to 50 years those without premenstrual mood symptoms and those with PMDD or severe premenstrual syndrome symptoms. Participants will collect blood samples at home using a dried blood spot system during both menstrual phases. The study also compares epigenetic markers between women with PMDD who have responded to selective serotonin reuptake inhibitor SSRI treatment and those who have not. Participants will be involved for about three months, during which their mood changes and biological samples will be collected and analyzed. The main outcome measured is the presence of DNA methylation biomarkers linked to PMDD and treatment response. This observational study monitors participants natural menstrual cycles and mood, with no treatment assigned, to better understand biological differences related to PMDD.

Identification and Validation of Epigenetic Biomarkers of PMDD